Congress Materials – European Hematology Association (EHA 2025)
2025 European Hematology Association | Jun 12-15 | Milan, Italy
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Absolute Lymphocyte Count as a Key Biomarker for Monitoring Safety After Ciltacabtagene Autoleucel Infusion
Yi Lin, Rocio Montes de Oca, Binod Dhakal, Roberto Mina, Salomon Manier, Paula Rodriguez-Otero, Yael C. Cohen, Dominik Dytfeld, Feng Wang, Katharine Henry, Ana Caroline Costa Sa, Tzu-Min Yeh, Ana Slaughter, Nikoletta Lendvai, Jieqing Zhu, Da Xu, Mythili Koneru, Nitin Patel, Vicki Plaks, Adam D. Cohen
A Global Phase 1b Study of JNJ-90014496, a CD19/CD20 Bi-Specific Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Krish Patel, Joanna Rhodes, Luke Mountjoy, Jacob Haaber Christensen, Martin Hutchings, Paul Shaughnessy, Nosha Fahadfar, Constantine Tam, John Baird, Aravind Ramakrishnan, Margot Jak, Kathleen Anne Dorritie, Allison Barraclough, Daniel Morillo, Yasmina Serroukh, Matthew Schwede, Ahmed Abdulgawad, Laura Magnano Mayer, Maeve O'Reilly, John Kuruvilla, Youngil Koh, Umar Farooq, Won Seog Kim, Jacqueline Bussolari, Melissa Beelen, Julie Larsen, Mahipal Suraneni, Jianmei Wu, Leen Slaets, Alfredo Perales-Puchalt, Arnob Banerjee, Matthew Ku
This document will be available on June 12 2025
A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen Targeting Calreticulin and JAK2 Mutations, in Combination With Ipilimumab in Patients With Myeloproliferative Neoplasms
Salman Otoukesh, Bethan Psaila, Andrew Kuykendall, Aaron Gerds, Ahmed Abdulgawad, Prithviraj Bose, Charlotte Van Bogaert, Jennifer Bishop, Patrick Wilkinson, Baolian Liu, Kevin Han, Busola Sanusi, Jaymala Patel, Katelyn Miller, Denis Smirnov, John Loffredo, M. Alejandro Sepulveda, Ricardo Attar, Kim Staquet, Charles G. Drake, Nikki Daskalakis, Claire Harrison
A Real-World Study of Lenalidomide Refractory Multiple Myeloma Patients in Finland: Treatment and Outcomes
Anu Partanen, Hege Susann Riisa, Johanna Vikkula, Marika Waltari, Riikka Mattila, Akseli Kivioja, Jonna Eeva, Mervi Putkonen
Ciltacabtagene Autoleucel (Cilta-cel) vs Standard of Care (SOC) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (MM): CARTITUDE-4 Survival Subgroup Analyses
Yaël C. Cohen, Joaquín Martínez-López, Abdullah M. Khan, Albert Oriol, Andrew Spencer, Binod Dhakal, Cyrille Touzeau, Dominik Dytfeld, Hermann Einsele, Jesús San-Miguel, Salomon Manier, Diana Chen, Quanlin Li, Tzu-min Yeh, Katherine Li, Vicki Plaks, Ana Slaughter, Nina Benachour, Carolina Lonardi, Arnab Ghosh, Martin Vogel, Nikoletta Lendvai, Tamar Lengil, Mythili Koneru, Nitin Patel, Octavio Costa Filho, Erika Florendo, Surbhi Sidana, Simon J. Harrison
Clinical Outcomes of Patients With Relapsed or Refractory Multiple Myeloma With and Without Extramedullary Disease
Peter M. Voorhees, Shaji Kumar, Saad Z. Usmani, Jing Christine Ye, Yaël C. Cohen, Emma Scott, Robin L. Carson, Christoph Heuck, Ryan Gan, Benjamin Ackerman, Jenny Zhang, Eleanor Caplan, Trilok Parekh, María-Victoria Mateos
Clinical Unmet Need of Lenalidomide-Refractory vs Non–Lenalidomide-Refractory Patients With Multiple Myeloma in the HONEUR Federated Data Network
Roman Hájek, Alexandra Jungova, Jiri Minarik, Frantisek Sedlak, Jakub Radocha, Jan Soukup, Ludek Pour, Blanca Gros Otero, Yuwei Wang, Michel Van Speybroeck, Joris Diels, Stefan Schilling, Guillaume Azarias, Markus Rückert
Cross-Study Comparison of Ibrutinib in Combination with Venetoclax (I+V) vs Acalabrutinib in Combination With Venetoclax (A+V) in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Talha Munir, José-Ángel Hernández-Rivas, Alessandra Tedeschi, Loic Ysebaert, John N. Allan, Claudio A. Schioppa, Suzy Van Sanden, Joris Diels, Liva Andersone, Mohamed Fouad
Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) vs VRD in Transplant-Ineligible/Transplant-Deferred Newly Diagnosed Multiple Myeloma: Phase 3 CEPHEUS Trial Cytogenetic Subgroup Analysis
Nizar J. Bahlis, Saad Z. Usmani, Thierry Facon, Sonja Zweegman, Christopher P. Venner, Marc Braunstein, Ludek Pour, Josep Marti, Supratik Basu, Yaël C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legiec, Angelo Maiolino, Mai Ngo, Maria Krevvata, Emilie van Brummelen, Lorena Lopez-Masi, Melissa Rowe, Robin L. Carson, Vania Hungria
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Subgroup Analysis of Transplant-Ineligible Patients in the Phase 3 CEPHEUS Study
Thierry Facon, Sonja Zweegman, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Ludek Pour, Josep Maria Martí-Tutusaus, Supratik Basu, Yaël C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Meral Beksac, Angelo Maiolino, Jianping Wang, Emilie van Brummelen, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin L. Carson, Saad Z. Usmani
Efficacy and Safety of First-Line Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma Who Were Older or Had TP53 Mutations in the SYMPATICO Study
Gottfried von Keudell, Marc Hoffmann, Tomasz Wrobel, Marek Trneny, David Belada, Fatih Demirkan, Panayiotis Panayiotidis, Wojciech Jurczak, Pier Luigi Zinzani, Mary-Margaret Keating, Sung-Soo Yoon, Miklós Egyed, Constantine S. Tam, Nathalie A. Johnson, Edith Szafer-Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Michael Wang
Exploratory Biomarkers Associated With Talquetamab Resistance and Relapse in the MonumenTAL-1 China 400 Cohort by Data-Driven Unsupervised Clustering Analysis
Hongmei Xu, Feng Wang, Deeksha Vishwamitra, Dianna Wu, Cuc Davis, Onsay Lau, Han Yang, Xue Gai, Liang Li, Rui Liu, Christoph Heuck, Thomas Renaud, Bonnie W. Lau, Tara J. Masterson, Michela Campagna, Lugui Qiu, Gang An, Xuesong Lyu, Christopher Chiu, Ricardo Attar, Michael Gormley, Longen Zhou
Final Analysis of Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study
William Wierda, Paul Barr, John Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas Kipps, Susan O'Brien, Ryan Jacobs, Xavier Badoux, Livio Trentin, Masa Lasica, Dennis Carney, Anna Elinder Camburn, Javier De La Serna, Edith Szafer-Glusman, Cathy Zhou, Jutta Neuenburg, Anita Szoke, Jim Dean, Constantine Tam, Paolo Ghia
This document will be available on June 12 2025
First-In-Human Study of JNJ-79635322 (JNJ-5322), a Novel, Next-Generation Trispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Initial Phase 1 Results
Rakesh Popat, Cyrille Touzeau, Aurore Perrot, Sébastien Anguille, Albert Oriol, Nicolas Kint, Jo Caers, Monique Minnema, Martin Kaiser, Hans Lee, Alfred Garfall, Jeffrey Matous, Larysa Sanchez, Azra Borogovac, Lionel Karlin, Laura Rosiñol, Wilfried Roeloffzen, Saad Z. Usmani, Cindy Varga, Darren Pan, Tadao Ishida, Pansy Minnick, Damiette Smit, Nikki Daskalakis, Thomas Prior, Maria Krevvata, Ashley Nguyen, Brandi Hilder, Daniel Jonathan, Joseph Weidman, Sangmin Lee, Maria-Victoria Mateos, Paula Rodríguez-Otero, Gala Vega, Niels W.C.J. van de Donk
This document will be available on June 12 2025
First Results From REALiTAL: A Multi-Country Observational Retrospective Study of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma Outside of Clinical Trials
Katarina Uttervall, Martin Kortüm, Aurore Perrot, Vitaliy Mykytiv, Hila Magen, Elisabetta Antonioli, Matteo Claudio Da Vià, Carmine Liberatore, Elena Zamagni, Markus Hansson, Maurizio Musso, Janusz Krawczyk, Tamir Shragai, Katja Weisel, Raphael Teipel, DoRota Knut-Bojanowska, Charlotte Toftmann Hansen, Patrick Hayden, Mathias Haenel, Marc-Steffen Raab, Fabrizio Pane, Sarah Leeth Farmer, Moshe Gatt, Valerio De Stefano, Bhuvan Kishore, Susanne Strifler, Rana Takchi, Peter Hu, Diptendu Santra, Vadim Strulev, Eva Rubio-Azpeitia, Eric Aeby, Krystof Subrt, Claire Albrecht, Natalia Martin Suñe, Rakesh Popat
First Worldwide Real-Life Data on Fixed-Duration Ibrutinib+Venetoclax Treatment for Previously Untreated CLL/SLL Patients: Initial Interim Analysis of Spain's LI+VE Observational Study
José-Ángel Hernández Rivas, Ana Muntañola, Esther Sancho Ponce, Ángeles Medina, Rafael Lluch García, Ana Carla De Oliveira, Alicia Rodríguez Fernández, Joan Alfons Soler, María José Terol Castera, Patricia Machado, Manuel Pérez Encinas, Rafael Romero Carmona, Lucreia Yáñez, Paloma García Martín, Laura García-Fontecha, Ana Alfayate Lobo
Health-Related Quality of Life in Patients With Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma (MM) in the Phase 3 CEPHEUS Trial
Vania Hungria, Saad Z. Usmani, Thierry Facon, Sonja Zweegman, Nizar J. Bahlis, Marc Braunstein, Ludek Pour, Josep M. Marti, Supratik Basu, Yaël C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Legieć, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Weiping Liu, Marjorie Nobrega, Jianping Wang, Eva G. Katz, Lorena Lopez-Masi, Jodi Carey, Fredrik Borgsten, Melissa Rowe, Robin L. Carson, Christopher P. Venner
IBROMICS: A Real-World Study of Clinical and Biological Parameters Determining Response in Patients with Chronic Lymphocytic Leukemia (CLL) Treated in First Line With Single Agent Ibrutinib
José Antonio García-Vela, José-Angel Hernández-Rivas, Francesc Bosch, Cecilia Muñoz-Calleja, Laura Palomo, Adrián Mosquera-Orgueira, Ángel Ramírez Payer, Ruben Fernandez Alvarez, Ana Carla Oliveira, Paula Amat, Alicia Serrano Alcala, Marta Crespo Maull, Ana Yeguas, Aránzazu García-Grande, Miguel Alcoceba Sánchez, Blanca Ferrer, Luis Espinosa-Hevia, Celia Bolumburu Camara, Miguel Villanueva Forero
Integrating the Carbon Footprint Into Health Technology Assessment in France: The Example of the Healthcare Pathway for Chronic Lymphocytic Leukaemia
Enora Alaoui, Aurélie Cabannes-Hamy, Mathis Egnell, Thelma Arcelin, Anne Elong, Aubrey Mulot, CE. Bednarek, Valentine Bourjot, Luca Inchiappa, Isabelle Durand-Zaleski, Sandrine Baffert, Caroline Besson
Long-term (≥5 Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath, Thomas Martin, Yi Lin, Adam Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesus Berdeja, Alexander Lesokhin, Binod Dhakal, Samir Parekh, Hui Li, Feng Wang, Rocio Montes de Oca, Vicki Plaks, Huabin Sun, Arnob Banerjee, Jordan Schecter, Nikoletta Lendvai, Deepu Madduri, Jieqing Zhu, Mythili Koneru, Nitin Patel, Andrzej Jakubowiak, Peter Voorhees
This document will be available on June 12 2025
Outcomes in patients with triple-class–exposed relapsed/refractory multiple myeloma treated with real-life standard-of-care therapies in LocoMMotion and MoMMent final data
Katja Weisel, María-Victoria Mateos, Max Bittrich, Maria Esther Gonzalez Garcia, Valerio De Stefano, Britta Besemer, Laure Vincent, Suriya Kirkpatrick, Lionel Karlin, Hartmut Goldschmidt, Concetta Conticello, Wilfried Roeloffzen, Niels W.C.J. van de Donk, Michel Delforge, Eilidh Duncan, Silene ten Seldam, Margaret Doyle, Kathleen S. Gray, Katharine S. Gries, Claire Albrecht, Lorenzo Acciarri, Jozefien Buyze, Nicholas Francella, Krystof Subrt, Philippe Moreau
Outpatient Step-Up Dosing and Safety With Talquetamab: A Real-World Mayo Clinic Study
Scott Soefje, Tyler Sandahl, Rafael Fonseca, Sikander Ailawadhi, Ricardo Parrondo, Nivedita Rangarajan, Hoa H. Le, Purushotham K., Hannah Barman, Tyler E. Wagner, Saurabh Patel, Xinke Zhang, Yi Lin, Shaji K. Kumar
Phase 2 Study of Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma and Extramedullary Disease: RedirecTT-1
Shaji Kumar, Maria-Victoria Mateos, Jing Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael P. Chu, Suzanne Trudel, Joshua Richter, Paula Rodríguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey Matous, Laura Rosiñol, Koichi Onodera, Surabhi Bajpai, Vikram Kurra, Emma Scott, Christoph Heuck, Jenny Zhang, Todd Henninger, Lisa O’Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiashen Lu, Nicholas Au, Maria Krevvata, Ashwini Kumar, Saad Z. Usmani, Yaël Cohen
This document will be available on June 12 2025
Preclinical Analysis of Ciltacabtagene Autoleucel Combination Strategies with T Cell Bispecifics and Daratumumab to Support Optimization of Clinical Benefit in Myeloma Patients
Douglas Marvel, Raj Kurupati, Gourav Choudhary, Joseph Portale, Mahipal Suraneni, Deeksha Vishwamitra, Nicholas Hein, Xuechen Wang, Nikoletta Lendvai, Jordan M. Schecter, J. Blake Bartlett, Jason Brayer, Vicki Plaks
Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome and Outpatient Dosing of Talquetamab in Relapsed/Refractory Multiple Myeloma: Updated Phase 1/2 MonumenTAL-1 Results
Dominik Dytfeld, Ravi Vij, Sundar Jagannath, Larysa Sanchez, Matthew Pianko, Andrzej Jakubowiak, Carolina Schinke, Jan Maciej Zaucha, María-Victoria Mateos, Tara J. Masterson, Michela Campagna, Veronique Vreys, Guoqiang Zhang, Kathleen S. Gray, Thomas Renaud, Bonnie W. Lau, Gareth Morgan
REALiTEC Subgroup Analysis: A Multi-Country Observational Retrospective Study of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Outside of Clinical Trials
Rakesh Popat, K. Martin Kortüm, Katarina Uttervall, Sarah Farmer, Michele Cavo, Bhuvan Kishore, Caroline Jacquet, Maria Casanova, Markus Hansson, Katja Weisel, Hila Magen, Carmine Liberatore, Charlotte Toftmann Hansen, Moshe Gatt, Tamir Shragai, Matteo Claudio Da Vià, Teresa De Soto Alvarez, Mathew Streetly, Marc-Steffen Raab, Salomon Manier, Jesper Aegesen, Rana Takchi, Peter Hu, Diptendu Santra, Vadim Strulev, Claire Albrecht, Eva Rubio-Azpeitia, Aurore Perrot
Real-world analysis of talquetamab in heavily pretreated and high-risk patients with relapsed/refractory multiple myeloma
Tala Shekarkhand, David Nemirovsky, Andriy Derkach, Kylee Maclachlan, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Sridevi Rajeeve, Hamza Hashmi, Gunjan Shah, Michael Scordo, Heather J. Landau, Sergio A. Giralt, Alexander Lesokhin, Neha Korde, Saad Z. Usmani, Yi-Hsuan Liu, Elissa E. Min, Xinke Zhang, Saurabh Patel, Carlyn Rose Tan
Real-World Characteristics and Safety and Effectiveness of Talquetamab Among Patients With Relapsed or Refractory Multiple Myeloma (RRMM): An Electronic Medical Record and Chart Review Study
Cesar Rodriguez, Hsien-yen Chang, Yi-hsuan Liu, Eric Chinaeke, Jinghua He, Jessica Maitland, Alvi A. Rahman, Anabelle Tardif-Samson, Alessio Palladino, Philippe Thompson-Leduc, Saurabh Patel, Xinke Zhang
Real-World Effectiveness of Belantamab Mafodotin, BCMA-CD3 Bispecifi Antibodies and Talquetamab in Patients With Triple-Class-Exposed Multiple Myeloma. Updated Data From the Danish ABCD-Study
Astrid Hundebøll Torpe, Jonathan Thorsen, Katrine Fladeland Iversen, Sarah Leeth Farmer, Thomas Lund, Charlotte Hansen, Lene Kongsgaard Nielsen, Nicolai Grønne Jørgensen, Maja Ølholm Vase, Elena Manuela Teodorescu, Christina Wennerström, Morten Salomo, Agoston Gyula Szabo
Retrospective, observational study to describe the clinical characteristics, management, and outcomes of bispecific anti-GPRC5D antibody in patients with relapsed refractory multiple myeloma treated outside clinical trials in Spain.
Maria Jesus Blanchard Rodriguez, Elena Fernandez Poveda, Esperanza Lavilla Rubira, Carolina Lopez Santamaria Castro, Pablo Lorente Alegre, José María Sánchez Pina, Miriam Gonzalez Pardo, Paula Rodríguez-Otero, Maria-Victoria Mateos
Retrospective Real-World Treatment Patterns and Outcomes in European Patients With Newly Diagnosed Multiple Myeloma Not Receiving Stem Cell Transplantation
Mamta Garg, Stefan Schilling, Guillaume Azarias, Markus Rückert, Giselle Lostaunau Costa, Nolen Perualila, Morten Salomo, Kristina Bardenheuer, Wout Vekemans, Joris Diels, Alexandra Jungova, Jiri Minarik, Frantisek Sedlak, Jakub Radocha, Jan Soukup, Ludek Pour, Roman Hájek
RP2D Determination of Bleximenib in Combination With VEN+AZA: Phase 1b Study in ND & R/R AML With KMT2A/NPM1 Alterations
Andrew H. Wei, Jordi Esteve Reyner, Sylvain Garciaz, Ibrahim Aldoss, Ana Alfonso Piérola, Alicia Allred, Juan Manuel Alonso Dominguez, Laura Barreyro, Pierre Bories, Nikki Daskalakis, Matteo Giovanni Della Porta, Hartmut Döhner, Amber D’Souza, James Dugan, Amir Fathi, Pasquale Fedele, Lucille Ferrante, Rachel Kobos, Stan Gaj, Ana Garrido Diaz, Sara Garrido Paniagua, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Danielle Trancucci, Tosin Bamidele, Madlen Jentzsch, Hagop Kantarjian, Marina Konopleva, Jan Krönke, Marie Luise Hütter-Krönke, Christina Loefgren, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Daniel Morillo, Jenny O' Nions, Kathryn Packman, Cristina Papayannidis, Christian Récher, Christoph Roellig, Olga Salamero, Prathap Nagarajahastri, Tim Sauer, Emma Searle, Natalia Tovar, Nicolas Vallet, Lachlin Vaughan, Gala Vega, Paresh Vyas, Uwe Platzbecker
This document will be available on June 12 2025
Subcutaneous Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Transplant-Eligible Newly Diagnosed Multiple Myeloma: Analysis of Sustained Minimal Residual Disease Negativity in the Phase 3 PERSEUS Trial
Philippe Moreau, Pieter Sonneveld, Hermann Einsele, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Huiling Pei, Diego Vieyra, Alba Tuozzo, Carla J. de Boer, Anna Sitthi-Amorn, Robin L. Carson, Paula Rodríguez-Otero, Meletios A. Dimopoulos, Mario Boccadoro
Survival Benefit of Ciltacabtagene Autoleucel in Second-Line Compared With Later-Line Treatment of Lenalidomide-Refractory Multiple Myeloma: Updated Treatment Positioning Model Analysis
Roberto Mina, Eunju Todd, Sandhya Nair, João Mendes, Jianming He, Nasuh Buyukkaramikli, Rafal Slowik, Seina Lee, Thomas G. Martin, Rafael Fonseca
Talquetamab + Cetrelimab in Patients With Relapsed/Refractory Multiple Myeloma: Initial Safety and Efficacy Results From the Phase 1b TRIMM-3 Study
Aurore Perrot, Cyrille Touzeau, Paula Rodríguez-Otero, Albert Oriol, Daniel Morillo, Raphael Teipel, John McKay, Larysa Sanchez, Jeffrey V. Matous, Muhamed Baljević, Xavier Leleu, Katja Weisel, Hermann Einsele, Hartmut Goldschmidt, Jesus G. Berdeja, Jue Gong, Deeksha Vishwamitra, Diana Cortes-Selva, Brendan Hodkinson, Nicolas Sauvageot, Kathleen Gray, Jenny Zhang, Mahadi Baig, M. Damiette Smit, Nikki Daskalakis, Daniel Jonathan, Sangmin Lee, María-Victoria Mateos, Laure Vincent, Saad Z. Usmani
This document will be available on June 12 2025
Talquetamab Immunogenicity and Impact on Exposure, Efficacy, and Safety: Analyses From Patients With Relapsed/Refractory Multiple Myeloma in MonumenTAL-1
Jue Gong, Thomas Renaud, Sheetal Khedkar, Brandi W. Hilder, Tara J. Masterson, Michela Campagna, Bonnie W. Lau, Bonnie Wu, Jenny Zhang, Nahor Haddish-Berhane, Indrajeet Singh
Talquetamab vs Real-World Physician’s Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen Therapy: Updated Analyses of MonumenTAL-1 vs LocoMMotion/MoMMent
María-Victoria Mateos, Andrzej Jakubowiak, Hermann Einsele, Carolina Schinke, Britta Besemer, Sébastien Anguille, Salomon Manier, Leo Rasche, Hartmut Goldschmidt, Niels W.C.J. van de Donk, Aurore Perrot, Raphael Teipel, Lionel Karlin, Christof Scheid, Jesús San-Miguel, Charlotte Pawlyn, Joaquín Martinez-Lopez, Michele Cavo, Joris Diels, Francesca Ghilotti, Bonnie W. Lau, Thomas Renaud, Oleksiy Orel, Fenny Ong, Diogo F. Ramos, Eric Ammann, Katja Weisel, Philippe Moreau
Updated Comparative Effectiveness of Talquetamab vs Real-World Physician’s Choice of Treatment in LocoMMotion and MoMMent for Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Hermann Einsele, Philippe Moreau, Nizar J. Bahlis, Manisha Bhutani, Laure Vincent, Lionel Karlin, Aurore Perrot, Hartmut Goldschmidt, Niels W.C.J. van de Donk, Enrique M. Ocio, Joaquín Martínez-López, Paula Rodríguez-Otero, Dominik Dytfeld, Joris Diels, Francesca Ghilotti, Bonnie W. Lau, Thomas Renaud, Fenny Ong, Diogo F. Ramos, Eric M. Ammann, Trilok Parekh, Claire Albrecht, Katja Weisel, María-Victoria Mateos
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.